1 2	Bivalent COVID-19 booster vaccines induce cross-reactive but not BA.5-specific antibodies in polyclonal serum				
3					
4 5 6	Juan Manuel Carreño ^{*&} , Gagandeep Singh [*] , Anass Abbad, Temima Yellin, Komal Srivastava, Charles Gleason, PVI study group, Harm van Bakel, Viviana Simon ^{&} and Florian Krammer ^{&}				
6 7 8	Affiliation: Icahn School of Medicine at Mount Sinai, New York, NY, USA				
9	*Contributed equally				
10	^{&} Corresponding authors: Florian Krammer (<u>florian.krammer@mssm.edu</u>), Viviana Simon				
11 12	(viviana.simon@mssm.edu), Juan Manuel Carreño (jm.carreno@mssm.edu)				
13 14	Abstract				
15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42	The question if the bivalent mRNA COVID-19 booster vaccination, containing wild type and BA.5 spike, provides enhanced benefits against BA.5 and similar Omicron subvariants has been widely debated. One concern was an 'original antigenic sin'-like effect which may redirect immune responses to the bivalent vaccine towards the wild type spike and may block <i>de novo</i> generation of BA.5 specific antibodies. Here, we characterized the response to the bivalent vaccine and we performed antibody depletion experiments. Interestingly, when we depleted serum of all antibodies to wild type RBD, we also removed all reactivity to BA.5 RBD. This suggests that all antibodies induced by the bivalent vaccine – at least with the limit of detection of our assay in polyclonal serum - are in fact cross-reactive. This further suggests that, on a serum antibody level, the bivalent vaccine did not induce a <i>de novo</i> response to BA.5.				
43 44					
45 46 47					

48	Bivalent COVID-19 booster vaccines induce cross-reactive but not BA.5-specific antibodies in
49	polyclonal serum
50	
51	
52	
53	
54	Vaccination against the coronavirus disease 2019 (COVID-19) increased immunity in the population
55	reducing viral transmission and protecting against severe disease. However, continuous emergence of
56	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants required the implementation of
57	bivalent boosters including the wild-type (WT_D614G) and BA 5 spike. Improved effectiveness of bivalent
58	vs monovalent booster against Omicron sub-variants was reported [1] however limited differences in the
59	immune response are detected [2] 3]
60	
61	We investigated whether a hivalent COVID-19 hooster vaccine comprised of WT + BA 5 spike induced
62	detectable BA 5-specific antibody responses in serum Samples (n=16) collected before [31 days +/- 63 (0
62	= 260) and after [16 +/- 8 days (6 = 31)] receiving the bivalent booster were tested for antibody binding
6/	= 200)] and after [10 1/2 0 days (0 = 51)] receiving the bivalent booster were tested for antibody binding and avidity to the recentor binding domain (PRD) of W/T and RA 5. Neutralization of W/T and RA 5 viruses
65	was determined. Omicron-specific antibodies were measured by depletion of W/T BBD reactive antibodies
66	and assessment of depleted sera against RA 5 PRD
67	and assessment of depicted seta against BA.5 KbD.
60	A significant increase in antihody binding to W/T and DA E DDD and in neutralization of W/T and DA E vigues
60	A significant increase in antibody binding to WT and BA.5 KbD and in neutralization of WT and BA.5 viruses
70	were detected following bivalent booster. There were significant differences in particulation were not significant. Dro, and
70	sera between with and BA.5 RBDs, nowever differences in neutralization were not significant. Pre- and
/1 72	post- booster RBD antibody availity was lower against BA.5 vs will RBD, which prompted us to look for BA.5
72 72	specific antibodies. Wi RBD depleted sera lacked reactivity to Wi RBD – as expected – and to BA.5 RBD,
75	suggesting that a single exposure to BA.5 antigens by the auministration of bivalent vaccine boosters does
74 75	not elicit robust levels of BA.5 specific serum antibodies.
75	Deduced consistivity of antibody tests based on W/T visal antigens was detected in noive individuals often
70 77	Created sensitivity of antibody tests based on with viral antigens was detected in haive individuals after
70	Omicron infection [4]. However, most of the population globally has been infected with ancestral strains
/ð 70	and/or exposed to will antigens through vaccination, hence our results are relevant for the current
/9	immune status of the population worldwide. Moreover, our data align with recent results indicating that
80	a monovalent booster with BA.1 vaccine elicits robust spike-specific germinal center B cell responses but
81	low levels of <i>de novo</i> B cells targeting variant-specific epitopes [5]. Whether further exposures to Omicron
82	antigens will boost these responses to make them detectable in serum remains to be explored.
83	Importantly, it is likely that cross-reactive antibodies towards Omicron-antigens contribute to protection.
84	
85	Juan Manuel Carreño, Ph.D.
86	Viviana Simon, MD, Ph.D.
87	Florian Krammer, Ph.D.
88	
89	Icahn School of Medicine at Mount Sinai, New York, USA
90	Tel. 212-241-0391
91	<u>Florian.krammer@mssm.edu</u>
92	<u>Viviana.simon@mssm.edu</u>
93	<u>Jm.carreno@mssm.edu</u>
94	
95	





96

100 Figure 1. (A) Antibody levels expressed as area under the curve (AUC), binding to the recombinant 101 receptor binding domain (RBD) of wild type (WT, blue) and BA.5 (red) SARS-CoV-2, measured in pre- and 102 post- bivalent booster vaccination (WT + BA.5) sera. (B) Inhibitory dilution 50% (ID50) of pre- and post-103 bivalent booster vaccination (WT + BA.5) sera vs WT (blue) and BA.5 (red) live viruses. (C) Avidity index 104 (AI) of pre- and post- bivalent booster vaccination (WT + BA.5) sera to WT (blue) and BA.5 RBD (red). (D) 105 Reactivity of pre (light blue)- and post (dark blue)- bivalent booster vaccination (WT + BA.5) sera depleted 106 of WT RBD antibodies (dashed lines) or non-depleted (continuous lines) towards WT (left) or BA.5 (right) 107 RBD. Dotted lines in A-B indicate the limit of detection of the assay. Dotted line in C indicates the threshold 108 for low avidity. In **D**, optical density (OD) in the y axis and reciprocal serum dilutions (100-12,800 with 2-109 fold dilution series) in the x axis are shown. A non-linear regression of log (10) transformed data is 110 presented. In A-C, average fold change after bivalent vaccine booster is indicated for every pair. A regular one-way analysis of variance (ANOVA) test with Tukey multiple-comparison was performed to compare 111 112 differences among groups. P values lower than 0.0332 were considered statistically significant with a 95% 113 confidence interval. * P < 0.0332; ** P < 0.0021; *** P < 0.0002; **** P < 0.0001. In **A-D**, geometric mean 114 (GM) plus 95% confidence interval (CI) is shown, n=16.

- 115
- 116
- 117
- 118
- 119

120	
121	
122	Author list
123	
124	Juan Manuel Carreño**
125	Gagandeep Singh*
126	Anass Abbad
127	Temima Yellin
128	Komal Srivastava
129	Charles Gleason
130	PVI study group
131	Harm van Bakel
132	Viviana Simon ^{&}
133	Florian Krammer ^{&}
134	
135	*Contributed equally
136	^{&} Corresponding authors: Florian Krammer (florian.krammer@mssm.edu), Viviana Simon
137	(viviana.simon@mssm.edu). Juan Manuel Carreño (im.carreno@mssm.edu)
138	·,
139	
140	Supplementary material
141	
142	Methods
142	
144	Ethics statement Sera and data were obtained from two observational studies: the PARIS study
145	(Protection Associated with Ranid Immunity to SARS-CoV-2, approved by the Program for the Protection
146	of Human Subjects at the Icahn School of Medicine at Mount Sinai Institutional Review Board IRB-20-
1/17	$03374/STUDY_{20}-00442$) and the observational longitudinal clinical sample collection from nationts with
1/18	emerging viral infections research study (approved by the Program for the Protection of Human Subjects
1/0	at the Icahn School of Medicine at Mount Sinai Institutional Peview Board, IPB-17-00701/STLIDY-16-
150	01215) Participants from both studies provided informed consent prior to sample and data collection
150	orzij. Participants nom both studies provided informed consent prior to sample and data conection.
151	Study schoot and some complex . Dead was called and from individuals before and after reseiving a Dfizer
152	Study conort and serum samples. Blood was collected from individuals before and after receiving a Prize (n=10) or Madama (n=0) bivelant version beaster of wild type 1. DA E enike. Complex were collected 21.
155	(n=10) or Moderna $(n=6)$ bivalent vaccine booster of wild type + BA.5 spike. Samples were collected 31
154	+/-63 (0 – 260) days before and 16 +/-8 (6 – 31) days after bivalent booster vaccination. No comorbidities
155	were reported by the participants. Detailed demographic characteristics and vaccination information per
156	individual and per group are indicated in Supplementary Tables 1 and 2 .
157	
158	Cells and viruses. African green monkey Vero.E6 cells expressing transmembrane protease serine 2
159	(IMPRSS2) were cultured at $3/^{\circ}$ C with 5% CO ₂ in Dulbecco's modified Eagle medium (DMEM, Thermo
160	Fisher Scientific) supplemented with 10% fetal bovine serum (FBS), 1× nonessential amino acids (NEAA),
161	1% penicillin-streptomycin, 3 µg/ml puromycin (InvivoGen) and 100 µg/ml Normocin (InvivoGen). The
162	SARS-CoV-2 isolate USA-WA1/2020 was used as wild-type reference (BEI Resources, NR-52281) and
163	USA/NY-MSHSPSP-PV58128/2022 provided by the Mount Sinai Pathogen Surveillance Program as
164	representative viral isolate for Omicron BA.5.
165	
166	Recombinant proteins. Recombinant soluble SARS-CoV-2 proteins were expressed using a mammalian
167	cell protein expression system. SARS-CoV-2 spike, RBD, and NP gene sequences from the ancestral strain

168 Wuhan-1 were cloned into a mammalian expression vector pCAGGs. Proteins were produced in Expi293F

- 169 cells (Thermo Fisher Scientific) using the ExpiFectamine 293 Transfection Kit (Thermo Fisher Scientific) for
- plasmid transfection. Spike and RBD cell culture supernatants were harvested at 3 days post-transfection,
- 171 centrifuged at 4000 x g, and filtered. Proteins were purified using Ni²⁺-nitrilotriacetic acid (Ni-NTA) agarose
 172 (Qiagen).. Purified proteins were concentrated using Amicon Ultracell centrifugal units (EMD Millipore),
- 172 (Glager)... Putnied proteins were concentrated using Anncon Otracen centriligat units (EMD Minipole), 173 and buffer was exchanged to phosphate buffered saline (PBS, pH 7.4). Protein integrity was assessed using
- sodium dodecyl sulphate (SDS) polyacrylamide gels (5–20% gradient; Bio-Rad). Proteins stocks were
- 175 stored at -80°C until used.
- 176

177 Binding and avidity measurements. Antibody binding and avidity levels were assessed using a research-178 grade enzyme-linked immunosorbent assay (ELISA). Recombinant receptor binding domain (RBD) from 179 the original Wuhan-Hu-1 SARS-CoV-2 isolate (wild-type, WT) and Omicron (BA.5) SARS-CoV-2 were used. 180 Sera was heat inactivated at 56°C for 1h. Ninety-six-well plates (Immulon 4 HBX; Thermo Scientific) were 181 coated with 50 μ /well of recombinant antigen (2 μ g/mL) in phosphate-buffered saline (PBS; pH 7.4, Gibco) 182 and incubated overnight at 4°C. Plates were washed 3 times with 1X PBS supplemented with 0.1% Tween-20 (PBS-T; Fisher Scientific) and blocked with 200 µl/well of 3% non-fat milk PBS-T for 1h at room-183 184 temperature (RT). Serum dilutions starting at 1:100 followed by 2-fold dilutions were prepared in 1% non-185 fat milk PBS-T. Blocking solution was removed and dilutions were added to the plates for 2h at RT. Plates 186 were washed 3 times with PBS-T. For avidity measurements, the same sample was incubated with 187 identical sample dilutions in side-by-side columns; one column was treated with 100 µl/well of 8M Urea 188 while the other was left untreated. Plates were incubated for 10 min, then washed as described above. 189 50 μl/well of anti-human IgG (Fab-specific, Sigma-Aldrich, A0293) conjugated to horseradish peroxidase 190 (HRP) prepared in 1% non-fat milk PBS-T at 1:3000 dilutions were added for 1h at RT. Plates were washed 191 3 times and 100 µl/well of o-phenylenediamine dihydrochloride (Sigmafast OPD; Sigma-Aldrich) were 192 added for 10min at RT. To stop the reaction, 50 µl/well of 3 M hydrochloric acid (Thermo Fisher) were 193 added. Optical density (OD) at 490 nm was measured using a Synergy 4 (BioTek) plate reader. Blank wells 194 without serum were used to assess background. Antibody levels expressed as area under the curve (AUC) 195 were calculated by subtracting the background plus three times the standard deviation of the OD. Avidity 196 index (AI) was calculated using the following formula: AI = (Urea-treated sample AUC/Non-treated sample 197 AUC) *100).

198

199 Antigen coupling to magnetic beads. Carboxyl magnetic beads (RayBiotech, Peachtree Corners, GA) were 200 coated with RBD from WT SARS-CoV-2 at a ratio of 35 μ g of antigen per 100 μ l of magnetic beads. Mock 201 beads were prepared using PBS (pH 7.4, Gibco) only instead of antigen. Briefly, 1ml of magnetic beads 202 was transferred to a 1.5ml microtube and washed twice with wash buffer consisting of PBS supplemented 203 with 0.1% BSA and 0.05% Tween-20. Beads were resuspended in 1ml of wash buffer and 350 µg of purified 204 N-terminal 6x his tagged WT RBD antigen were added. The mixture was incubated for 2 h at 4°C with 205 constant shaking. Unbound antigen was removed by passage of beads through a magnetic stand. Coupled 206 beads were quenched by the addition of 1ml (1x volume of beads) of 50 mM Tris, (pH 7.4) and incubation 207 at RT with constant shaking. Quenching buffer was removed using the magnetic stand and conjugated 208 beads were washed 4 times with wash buffer. After the final wash, beads were resuspended in 1ml of 209 wash buffer (1x volume of beads) and stored at 4°C prior to use for antibody depletion.

210

Antibody depletion. Depletion of antibodies binding to WT RBD was performed using antigen coupled magnetic beads. Sera were diluted in PBS at a 1:10 ratio and 20 µl of antigen coupled magnetic beads or mock beads were added to 100 µl of pre-diluted sera. The mixture was incubated for 2 hours at 4°C with constant shaking. A magnet stand was used to constant the antibody antigen bound heads from the 1x

constant shaking. A magnet stand was used to separate the antibody-antigen-bound beads from the 1x

depleted sera. 20 ul of new antigen-coupled beads were added to the 1x depleted sera followed by the same incubation steps as the first round of depletion. 2x depleted sera was used for binding experiments.

217

218 Microneutralization assay. Serum samples were screened for neutralizing antibodies against ancestral 219 SARS-CoV-2 USA-WA1/2020 and BA.5. Briefly, 96-well plates were seeded with 2x10⁴ Vero.E6 TMPRSS2 220 cells per well in complete Dulbecco's modified Eagle medium (cDMEM) 24 hours before infection. Sera 221 were prediluted 1:10 in infection media consisting of minimal essential media (MEM; Gibco, cat. no. 222 11430-030) supplemented with 2 mM L-glutamine (Gibco, cat. no. 25030081), 0.1% sodium bicarbonate 223 (w/v) (HyClone, cat. no. SH30033.01), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; 224 Gibco, cat. no. 15630080), 100 U ml-1 penicillin, 100 µg ml-1 streptomycin (Gibco, cat. no. 15140122) 225 and 0.2% bovine serum albumin (BSA) (MP Biomedicals, cat. no. 810063). On the second day, serum 226 dilutions were incubated with 10,000 tissue culture infectious dose 50% (TCID50) of virus per ml for one 227 hour at RT. 120 µl of the virus-serum mix were transfered to every well of Vero.E6 TMPRSS2 plates, 228 followed by incubation for 1h at 37°C. Remdesivir (Medkoo Bioscience inc., cat. no. 329511) was used as 229 a control of virus inhibition at an initial concentration of 10 μ g/ml. Viral inoculum was removed and 100 µl/well of the respective serum dilutions plus 100 µl/well of infection media supplemented with 2% fetal 230 231 bovine serum (FBS; Gibco, Ref. 10082-147) were added. Infection was allowed to proceed for 48 hours at 232 37 °C. For nucleoprotein (NP) antigen staining, cell monolayers were fixed with 200 µl of 10% 233 paraformaldehyde (PFA) overnight at 4 °C. Cells were washed with 1x PBS then permabilized with 150 234 µl/well of PBS (pH 7.4) containing 0.1 percent Triton X-100 for 15 minutes at RT. Plates were blocked for 235 1 hour at RT with 200 µl/well PBS supplemented with 3% BSA. Blocking solution was removed and 100 236 µl/well of biotinylated monoclonal antibody (mAb) 1C7C7 (mouse anti-SARS NP monoclonal antibody 237 produced at The Icahn School of Medicine at Mount Sinai (ISMMS)) was added at 1 μ g/ml in PBS 238 supplemented with 1% BSA for1 hour at RT. Cells were washed with 200 µl/well of PBS twice and 239 100 µl/well of HRP-conjugated streptavidin (Thermo Fisher Scientific) diluted in PBS supplemented with 240 1% BSA were added at a 1:2,000 dilution for 1 h at room temperature. Plates were washed twice with PBS 241 and 100 µl/well of Sigmafast OPD were added for 10 minutes at RT. To stop the reaction, 50 µl/well of a 242 3 M HCl solution (Thermo Fisher Scientific) were added. Optical density (OD, 490 nm) was measured in a 243 Synergy H1 microplate reader (Biotek). For analysis and data representation Prism 9 (GraphPad) was used. 244 Percentage of neutralization, after background subtraction, and compared to the "virus only" control, was 245 calculated. Inhibitory dilution 50% (ID50) was calculated by a non-linear regression curve fit analysis with 246 top and bottom constraints of 100% and 0%, respectively. 247

Statistics. Differences between groups were assessed using a regular one-way analysis of variance
 (ANOVA) test with Tukey multiple-comparison. P values lower than 0.0332 were considered statistically
 significant with a 95% confidence interval. Statistical analyses were performed using Prism 9 (GraphPad,
 USA).

- 252
- 253 Financial support
- 254

255 We thank all the participants of the Personalized Virology Initiative's longitudinal studies for their 256 generous and continued support of research. This effort was supported by the Serological Sciences 257 Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of 258 Health, under Contract No. 75N91019D00024, Task Order No. 75N91021F00001. The content of this 259 publication does not necessarily reflect the views or policies of the Department of Health and Human 260 Services, nor does mention of trade names, commercial products or organizations imply endorsement by 261 the U.S. Government. This work was also partially funded by the Centers of Excellence for Influenza 262 Research and Surveillance (CEIRS, contract # HHSN272201400008C), the Centers of Excellence for

Influenza Research and Response (CEIRR, contract # 75N93021C00014), by the Collaborative Influenza
 Vaccine Innovation Centers (CIVICs contract # 75N93019C00051) and by institutional funds.

PVI Study Group: Miriam Fried, Sara Morris, Leeba Sullivan, Hala Alshammary, Dalles Andre, Maria C
Bermúdez-González, Gianna Cai, Christian Cognigni, Ana Gonzalez-reiche, Hyun Min Kang, Giulio Kleiner,
Neko Lyttle, Jacob Mauldin, Brian Monahan, Jessica Nardulli, Annika Oostenink, Jose Polanco, Ashley
Salimbangon, Morgan Van Kesteren.

272 Conflict of interest statement

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Dr. Simon is listed on the SARS-CoV-2 serological assays patent. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Dr. Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and Avimex and he is a co-founder and scientific advisory board member of CastleVax. The Krammer laboratory is also collaborating with Pfizer on animal models for SARS-CoV-2.

282 Author contributions

J.M.C. and F.K. conceptualized study; V.S., C.G., K.S., and the PVI study group enrolled participants, collected data, evaluated surveys, managed IRB approvals, and provided biospecimen and metadata, G.S., T.Y., and J.M.C. performed experiments; H.v.B. performed sequencing of viral isolates; J.M.C., G.S., and A.A. analyzed data; J.M.C., V.S., and F.K. administered the project; F.K., V.S., and H.v.B. provided resources; J.M.C. and F.K. wrote original draft. All authors reviewed, edited and approved the final version of the manuscript, and have had access to the raw data. Members of the PVI study group collected, processed, stored biospecimen, curated metadata, conducted SARS-CoV-2 precision surveillance and assisted with serological antibody measurements.

Supplementary Table 1. Detailed description of samples used and demographics per individual.

Participant	Age	Sex	Ancestry	Time points	SARS CoV-2	Primary	Bivalent
ID ¹	Bracket			included in	infection	Vaccine	booster
				this study	prior to	type	type
					vaccination		
	25.20		a :			50	
BVB-1	35-39	Male	Caucasian	Pre-Boost,	NO	Pfizer	Moderna
			Not Hispanic or Latino	Post Boost			20
BVB-2	55-59	Male	Caucasian	Pre-Boost,	Yes	Moderna	Pfizer
			Hispanic or Latino	Post Boost			
BVB-4	45-49	Male	Caucasian	Pre-Boost,	Yes	Pfizer	Pfizer
			Not Hispanic or Latino	Post Boost			
BVB-5	40-44	Female	Other	Pre-Boost,	Yes	Pfizer	Moderna
			Not Hispanic or Latino	Post Boost			
BVB-6	45-49	Male	Other	Pre-Boost,	Yes	Pfizer	Moderna
			Not Hispanic or Latino	Post Boost			
BVB-7	35-39	Female	Caucasian	Pre-Boost,	Yes	Pfizer	Pfizer
			Not Hispanic or Latino	Post Boost			
BVB-8	40-44	Female	Caucasian	Pre-Boost,	Yes	Pfizer	Pfizer
			Not Hispanic or Latino	Post Boost			
BVB-9	65-69	Male	Caucasian	Pre-Boost,	Yes	Pfizer	Pfizer
			Not Hispanic or Latino	Post Boost			
BVB-10	40-44	Female	Caucasian	Pre-Boost,	No	Pfizer	Moderna
			Not Hispanic or Latino	Post Boost			
BVB-11	30-34	Female	Caucasian	Pre-Boost,	Yes	Pfizer	Pfizer
			Not Hispanic or Latino	Post Boost			
BVB-12	60-64	Female	Caucasian	Pre-Boost,	Yes	Pfizer	Pfizer
			Not Hispanic or Latino	Post Boost			
BVB-13	40-44	Female	Caucasian	Pre-Boost,	No	Pfizer	Pfizer
			Not Hispanic or Latino	Post Boost			
BVB-14	70-79	Female	Caucasian	Pre-Boost,	No	Pfizer	Moderna
			Not Hispanic or Latino	Post Boost			
BVB-15	40-44	Female	Caucasian	Pre-Boost,	Yes	Pfizer	Moderna
			Not Hispanic or Latino	Post Boost			
BVB-16	45-49	Female	Caucasian	Pre-Boost,	No	Pfizer	Pfizer
			Not Hispanic or Latino	Post Boost			
BVB-17	70-79	Male	Caucasian	Pre-Boost,	Yes	Pfizer	Pfizer
			Hispanic or Latino	Post Boost			

Summary of the demographic, infection and vaccination histories of participants from whom serum
 samples were analyzed. The following abbreviations are used in the table, Pre-Boost: serum collected
 before the bivalent vaccine booster, Post Boost: serum collected after the bivalent vaccine booster.

¹This is a code (bivalent booster/BVB abbreviation plus random number), not a patient ID.

325

326

327

328

Supplementary Table 2. Age and sex characteristics of individuals per group.

	Number of participants	16
Overall	Average age (min – max)	48 (32 – 73)
Overall	Average days before bivalent booster +/- stdv (min – max)	31 +/- 63 (0 - 260)
	Average days after bivalent booster +/- stdv (min – max)	16 +/- 8 (6 - 31)
	Number of participants	6
Mala	Average age (min – max)	53 (37 – 73)
Wale	Average days before bivalent booster +/- stdv (min – max)	13 +/- 17 (0 - 38)
	Average days after bivalent booster +/- stdv (min – max)	17 +/- 8 (10 - 28)
	Number of participants	10
Fomalo	Average age (min – max)	45 (32 – 73)
Feiliale	Average days before bivalent booster +/- stdv (min – max)	41 +/- 78 (2 - 260)
	Average days after bivalent booster +/- stdv (min – max)	15 +/- 9 (6 - 31)

The following abbreviations are used in the table: standard deviation (stdv), minimum (min), maximum (max).

- 331
- 332
- 333 334

335 References336

- 3371.Lin, D.Y., et al., Effectiveness of Bivalent Boosters against Severe Omicron Infection. N Engl338J Med, 2023. 388(8): p. 764-766.
- 339 2. Kurhade, C., et al., Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1
 340 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med, 2023. 29(2): p. 344-347.
- Wang, Q., et al., Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. N Engl J Med,
 2023. 388(6): p. 567-569.
- Rossler, A., et al., *Reduced sensitivity of antibody tests after omicron infection*. Lancet
 Microbe, 2023. 4(1): p. e10-e11.
- 3455.Alsoussi, W.B., et al., SARS-CoV-2 Omicron boosting induces de novo B cell response in
humans. Nature, 2023.
- 347